JC viremia in natalizumab-treated patients with multiple sclerosis

New England Journal of Medicine

Volumn 368, Issue 23, 2013, Pages 2240-2241

  Major, Eugene O ^a   Frohman, Elliot ^b   Douek, Daniel ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY TITER; HUMAN; JC VIRUS; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIREMIA; VIRUS TITRATION;

EID: 84878594740     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1214233     Document Type: Letter

References (5)

1. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010;68:384-91.
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
3. Perkins MR, Ryschkewitsch CF, Liebner JC, et al. Changes in JC virus specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog 2012;8(11):e1003014.
4. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78:1736-42.
5. Major EO, Ryschkewitsch CF, Jensen PN, et al. Persistence of JCV in natalizumab treated MS patients who developed PML. Ann Neurol 2011;69:430.